Role of RLIP76 in doxorubicin resistance in lung cancer (review)

Rit Vatsyayan, Pankaj Chaudhary, Poorna Chandra Rao Lelsani, Preeti Singhal, Yogesh C. Awasthi, Sanjay Awasthi, Sharad S. Singhal

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.

Original languageEnglish
Pages (from-to)1505-1511
Number of pages7
JournalInternational journal of oncology
Issue number6
StatePublished - 2009


  • Cancer
  • Doxorubicin
  • Drug-resistance
  • Glutathione conjugate transport
  • PKCα
  • RLIP76


Dive into the research topics of 'Role of RLIP76 in doxorubicin resistance in lung cancer (review)'. Together they form a unique fingerprint.

Cite this